FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155183904> ?p ?o ?g. }

• W2155183904 endingPage "546" @default.
• W2155183904 startingPage "540" @default.
• W2155183904 abstract "The objectives of this phase I trial were to determine the maximum tolerated dose (MTD) and the recommended dose (RD) for phase II/III trials of doxorubicin (DOX) combined with paclitaxel (PTX) and cisplatin (CDDP) in patients with advanced ovarian cancer (AOC).Twenty-eight patients with stage III/IV AOC received fixed doses of PTX (110 mg/m(2) over 24 h on day 1) and CDDP (75 mg/m(2) on day 2) and an escalating dose of DOX (20, 30, 40 or 50 mg/m(2) on day 1) every 3 weeks. The patients received up to six cycles of chemotherapy. At level 1, one of the original dose-limiting toxicities (DLTs), grade (G) 4 neutropenia lasting for 4 days or longer, occurred in four of six patients. The criterion for DLT was amended to 'G4 neutropenia lasting for 8 days or longer accompanied with G4 leukopenia' and four additional patients were evaluated at level 1.According to the new criteria, DLT was observed only in one of nine patients except one ineligible patient at level 1 and two of six patients at level 4. G4 neutropenia and G4 leukopenia occurred in 85% and 44%, respectively, in the first course of chemotherapy. Non-hematological toxicity was generally mild or moderate. MTD was not determined at the planned dose levels. A clinical response was observed in 16 of 19 (84%) evaluable patients. Further dose escalation was not performed and RD was determined as level 4 because more than 30% of cycles required some modification of chemotherapy at level 4.The combination of TAP including 50 mg/m(2) of DOX is feasible and well tolerated as first line chemotherapy in AOC, warranting further study of this regimen." @default.
• W2155183904 created "2016-06-24" @default.
• W2155183904 creator A5048562907 @default.
• W2155183904 date "2004-09-01" @default.
• W2155183904 modified "2023-10-06" @default.
• W2155183904 title "Cisplatin, Paclitaxel and Escalating Doses of Doxorubicin (TAP) in Advanced Ovarian Cancer: a Phase I Trial" @default.
• W2155183904 cites W1673544031 @default.
• W2155183904 cites W1723772693 @default.
• W2155183904 cites W174811711 @default.
• W2155183904 cites W1898738795 @default.
• W2155183904 cites W1930308991 @default.
• W2155183904 cites W1938913042 @default.
• W2155183904 cites W1940922428 @default.
• W2155183904 cites W2006913030 @default.
• W2155183904 cites W2010318242 @default.
• W2155183904 cites W2014439227 @default.
• W2155183904 cites W2022431174 @default.
• W2155183904 cites W2034009362 @default.
• W2155183904 cites W2035374326 @default.
• W2155183904 cites W2057417953 @default.
• W2155183904 cites W2084092457 @default.
• W2155183904 cites W2097105130 @default.
• W2155183904 cites W2102551452 @default.
• W2155183904 cites W2123107901 @default.
• W2155183904 cites W2130941707 @default.
• W2155183904 cites W2133635118 @default.
• W2155183904 cites W2167805334 @default.
• W2155183904 cites W2224253371 @default.
• W2155183904 cites W2261061437 @default.
• W2155183904 cites W2328421677 @default.
• W2155183904 cites W2395678656 @default.
• W2155183904 cites W2402400567 @default.
• W2155183904 cites W2406157896 @default.
• W2155183904 cites W2437358437 @default.
• W2155183904 cites W2440995134 @default.
• W2155183904 cites W2466460916 @default.
• W2155183904 cites W2519869343 @default.
• W2155183904 cites W25774907 @default.
• W2155183904 cites W2796504081 @default.
• W2155183904 cites W370487 @default.
• W2155183904 doi "https://doi.org/10.1093/jjco/hyh098" @default.
• W2155183904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15466828" @default.
• W2155183904 hasPublicationYear "2004" @default.
• W2155183904 type Work @default.
• W2155183904 sameAs 2155183904 @default.
• W2155183904 citedByCount "7" @default.
• W2155183904 countsByYear W21551839042012 @default.
• W2155183904 countsByYear W21551839042015 @default.
• W2155183904 countsByYear W21551839042020 @default.
• W2155183904 countsByYear W21551839042021 @default.
• W2155183904 countsByYear W21551839042022 @default.
• W2155183904 crossrefType "journal-article" @default.
• W2155183904 hasAuthorship W2155183904A5048562907 @default.
• W2155183904 hasBestOaLocation W21551839041 @default.
• W2155183904 hasConcept C121608353 @default.
• W2155183904 hasConcept C126322002 @default.
• W2155183904 hasConcept C141071460 @default.
• W2155183904 hasConcept C2776694085 @default.
• W2155183904 hasConcept C2777063308 @default.
• W2155183904 hasConcept C2777292972 @default.
• W2155183904 hasConcept C2778239845 @default.
• W2155183904 hasConcept C2778850193 @default.
• W2155183904 hasConcept C2780427987 @default.
• W2155183904 hasConcept C2780873365 @default.
• W2155183904 hasConcept C2781303535 @default.
• W2155183904 hasConcept C29730261 @default.
• W2155183904 hasConcept C31760486 @default.
• W2155183904 hasConcept C71924100 @default.
• W2155183904 hasConcept C90924648 @default.
• W2155183904 hasConceptScore W2155183904C121608353 @default.
• W2155183904 hasConceptScore W2155183904C126322002 @default.
• W2155183904 hasConceptScore W2155183904C141071460 @default.
• W2155183904 hasConceptScore W2155183904C2776694085 @default.
• W2155183904 hasConceptScore W2155183904C2777063308 @default.
• W2155183904 hasConceptScore W2155183904C2777292972 @default.
• W2155183904 hasConceptScore W2155183904C2778239845 @default.
• W2155183904 hasConceptScore W2155183904C2778850193 @default.
• W2155183904 hasConceptScore W2155183904C2780427987 @default.
• W2155183904 hasConceptScore W2155183904C2780873365 @default.
• W2155183904 hasConceptScore W2155183904C2781303535 @default.
• W2155183904 hasConceptScore W2155183904C29730261 @default.
• W2155183904 hasConceptScore W2155183904C31760486 @default.
• W2155183904 hasConceptScore W2155183904C71924100 @default.
• W2155183904 hasConceptScore W2155183904C90924648 @default.
• W2155183904 hasIssue "9" @default.
• W2155183904 hasLocation W21551839041 @default.
• W2155183904 hasLocation W21551839042 @default.
• W2155183904 hasLocation W21551839043 @default.
• W2155183904 hasOpenAccess W2155183904 @default.
• W2155183904 hasPrimaryLocation W21551839041 @default.
• W2155183904 hasRelatedWork W1511187821 @default.
• W2155183904 hasRelatedWork W2003420178 @default.
• W2155183904 hasRelatedWork W2025689023 @default.
• W2155183904 hasRelatedWork W2034308419 @default.
• W2155183904 hasRelatedWork W2182522919 @default.
• W2155183904 hasRelatedWork W2357273538 @default.
• W2155183904 hasRelatedWork W2361544313 @default.
• W2155183904 hasRelatedWork W2367148332 @default.

• next